Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;10(6):1734-46.
doi: 10.4161/hv.28462. Epub 2014 Mar 17.

HIV-1 vaccines: challenges and new perspectives

Jean-Louis Excler  1 , Merlin L Robb  1 , Jerome H Kim  2
Affiliations
Review

HIV-1 vaccines: challenges and new perspectives

Jean-Louis Excler et al. Hum Vaccin Immunother. 2014.

Abstract

The development of a safe and effective preventive HIV-1 vaccine remains a public health priority. Despite scientific difficulties and disappointing results, HIV-1 vaccine clinical development has, for the first time, established proof-of-concept efficacy against HIV-1 acquisition and identified vaccine-associated immune correlates of risk. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop correlated with decreased risk of HIV infection, while Env-specific IgA directly correlated with increased risk. The development of vaccine strategies such as improved envelope proteins formulated with potent adjuvants and DNA and vectors expressing mosaics, or conserved sequences, capable of eliciting greater breadth and depth of potentially relevant immune responses including neutralizing and non-neutralizing antibodies, CD4+ and CD8+ cell-mediated immune responses, mucosal immune responses, and immunological memory, is now proceeding quickly. Additional human efficacy trials combined with other prevention modalities along with sustained funding and international collaboration remain key to bring an HIV-1 vaccine to licensure.

Keywords: HIV-1; clinical trial; correlates; efficacy; licensure; public health; vaccine.

PubMed Disclaimer

Figures

None
Figure 1. Possible vaccine-induced immune mechanisms of protection against HIV-1 acquisition in humans.
See this image and copyright information in PMC

References

    1. UNAIDS Report on the Global AIDS Epidemic 2013. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiolo...
    1. McCoy SI, Kangwende RA, Padian NS. Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review. AIDS Behav. 2010;14:469–82. doi: 10.1007/s10461-009-9644-9. - DOI - PubMed
    1. Dutta A, Wirtz AL, Baral S, Beyrer C, Cleghorn FR. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS. 2012;7:362–8. doi: 10.1097/COH.0b013e328354a0b5. - DOI - PubMed
    1. Wamai RG, Morris BJ, Bailis SA, Sokal D, Klausner JD, Appleton R, Sewankambo N, Cooper DA, Bongaarts J, de Bruyn G, et al. Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J Int AIDS Soc. 2011;14:49. doi: 10.1186/1758-2652-14-49. - DOI - PMC - PubMed
    1. Chi BH, Adler MR, Bolu O, Mbori-Ngacha D, Ekouevi DK, Gieselman A, Chipato T, Luo C, Phelps BR, McClure C, et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President’s Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr. 2012;60(Suppl 3):S78–87. doi: 10.1097/QAI.0b013e31825f3284. - DOI - PMC - PubMed

Publication types

MeSH terms